The Austrian fulvestrant registry: Results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 115, Issue 2, 2009, Pages 373-380

  Bartsch, Rupert ^a   Mlineritsch, Brigitte ^b   Gnant, Michael ^a   Niernberger, Thomas ^c   Pluschnig, Ursula ^a   Greil, Richard ^b   Wenzel, Catharina ^a   Sevelda, Paul ^c   Thaler, Josef ^c   Rudas, Margaretha ^a   Pober, Michael ^c   Zielinski, Christoph C ^a   Steger, Guenther G ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c LKH Leoben ^*

Author keywords

Endocrine treatment; Fulvestrant; Metastatic breast cancer; Oestrogen receptor

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FULVESTRANT; LETROZOLE; TAMOXIFEN;

ADULT; AGED; ARTHRALGIA; ARTICLE; AUSTRIA; BREAST ADENOCARCINOMA; CANCER REGISTRY; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION SITE REACTION; INTRADUCTAL CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOEMBOLISM; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AUSTRIA; BREAST NEOPLASMS; ESTRADIOL; FEMALE; GENES, ERBB-2; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES;

EID: 67349164040     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0132-0     Document Type: Article

References (38)

1. J O'Shaughnessy 2005 Extending survival with chemotherapy in metastatic breast cancer Oncologist 10 3 20 29 10.1634/theoncologist.10-90003-20
2. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 1618 10.1056/NEJM199811263392207
3. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0
4. R Paridaens L Dirix C Lohrisch 2003 Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer Ann Oncol 14 1391 1398 10.1093/annonc/mdg362
5. E Bajetta G Procopio L Ferrari 2002 A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma Cancer 94 299 304 10.1002/cncr.10239
6. J Bonneterre A Buzdar JM Nabholtz 2001 Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced beast carcinoma Cancer 92 2247 2258 10.1002/1097-0142(20011101)92:9<2247::AID- CNCR1570>3.0.CO;2-Y
7. M Dutertre CL Smith 2000 Molecular mechanisms of selective estrogen receptor modulator (SERM) action J Pharmacol Exp Ther 295 431 437
8. R Schiff SA Massarweh J Shou 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin Cancer Res 10 1 Pt 2 331 336 10.1158/1078-0432.CCR-031212
9. M Sun JE Paciga RI Feldman 2001 Phosphatidylinostol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (Erα) via interaction between Erα and PI3K Cancer Res 61 5985 5991
10. IE Smith M Dowsett 2003 Aromatase inhibitors in breast cancer N Engl J Med 348 2431 2442 10.1056/NEJMra023246
11. WR Miller JM Bartlett P Canney 2007 Hormonal therapy for postmenopausal breast cancer: the science of sequencing Breast Cancer Res Treat 103 149 160 10.1007/s10549-006-9369-7
12. LF Macedo G Sabnis A Brodie 2008 Preclinical modeling of endocrine response and resistance Cancer 112 Suppl 3 679S 688S 10.1002/cncr.23191
13. AE Wakeling M Dukes J Bowler 1991 A potent specific pure antiestrogen with clinical potential Cancer Res 51 3867 3873
14. SE Fawell R White S Hoare 1990 Inhibition of estrogen receptor-DNA binding by the "pure" anti-estrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization Proc Natl Acad Sci USA 87 6883 6888 10.1073/pnas.87.17.6883
15. AE Wakeling 2000 Similarities and distinctions in the mode of action of different classes of antioestrogens Endocr Relat Cancer 7 17 28 10.1677/erc.0.0070017
16. A Howell 2006 Is fulvestrant ("faslodex") just another selective estrogen receptor modulator? Int J Gynecol Cancer 16 Suppl 2 521S 523S 10.1111/j.1525-1438.2006.00686.x
17. CK Osborne J Shou S Massarweh 2005 Crosstalk between estrogen receptor and growth factor receptor pathways is a cause for endocrine resistance in breast cancer Clin Cancer Res 11 2 Pt 2 865 870
18. N Normanno M Di Maio E De Maio 2005 Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr Relat Cancer 12 721 747 10.1677/erc.1.00857
19. R Bartsch C Wenzel G Altorjai 2007 Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment Clin Cancer Res 13 4435 4439 10.1158/1078-0432.CCR-06-3050
20. JF Robertson GG Steger P Neven 2007 Fulvestrant in the treatment of Her2-positive advanced breast cancer (ABC) J Clin Oncol 25 Suppl 18 47S 10.1200/JCO.2006.09.3146
21. A Howell JFR Robertson J Quaresma Albano 2002 Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 3396 3403 10.1200/JCO.2002.10.057
22. CK Osborne J Pippen SE Jones 2002 Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 386 3395 10.1200/JCO.2002.10.058
23. JF Robertson CK Osborne A Howell 2003 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women-a prospective combined analysis of two multicenter trials Cancer 98 229 238 10.1002/cncr.11468
24. GG Steger R Bartsch C Wenzel 2005 Fulvestrant ("Faslodex") in pre-treated patients with advanced breast cancer: a single-centre experience Eur J Cancer 41 2655 2661
25. GG Steger M Gips SD Simon 2005 Fulvestrant ("Faslodex"): Clinical experience from the Compassionate Use Programme Cancer Treat Rev 31 Suppl 2 10S 16S 10.1016/j.ctrv.2005.08.009
26. B Mlineritsch O Psenak P Mayer 2007 Fulvestrant (.,faslodex") in heavily pretreated postmenopausal patients with advanced breast cancer: Single centre clinical experience from the Compassionate Use Programme Breast Cancer Res Treat 106 105 112 10.1007/s10549-006-9482-7
27. S Chia W Gradisher L Mauriac 2008 Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromtase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 1664 1670 10.1200/JCO.2007.13.5822
28. P Neven R Paridaens G Pelgrims 2008 Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study Breast Cancer Res Treat 109 59 65 10.1007/s10549-007-9628-2
29. I Vergote JFR Robertson U Kleeberg 2003 Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy Breast Cancer Res Treat 79 207 211 10.1023/A:1023983032625
30. A Howell 2002 Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies Breast Cancer Res Treat 76 Suppl 1 72S
31. L Perey R Paridaens H Hawle 2007 Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss group for Clinical Cancer Research Trial (SAKK 21/00) Ann Oncol 18 64 69 10.1093/annonc/mdl341
32. S Beslija J Bonneterre H Burstein 2007 Second consenus on medical treatment of metastatic breast cancer Ann Oncol 18 215 225 10.1093/annonc/mdl155
33. G Arpino H Weiss AV Lee 2005 Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance J Natl Cancer Inst 97 1254 1261
34. M Stendhal L Ryden B Nordenskjold 2006 High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients Clin Cancer Res 12 4614 4618 10.1158/1078-0432.CCR-06- 0248
35. MJ Ellis A Coop B Singh 2003 Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status Cancer Res 63 6523 6531
36. RI Nicholson RA McClelland JF Robertson 1999 Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer Endocr Relat Cancer 6 373 387 10.1677/erc.0.0060373
37. CK Osborne R Schiff SA Fuqua 2001 Estrogen receptor: Current understandings of its activation and modulation Clin Cancer Res 7 Suppl 12 4338S 4342S
38. A Howell JFR Robertson P Abram 2004 Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J Clin Oncol 22 1605 1613 10.1200/JCO.2004.02.112